Novo Nordisk’s Wegovy: Decoding Its Regulatory Status in India

While Wegovy has gained traction globally for treating metabolic liver disease, its formal clinical approval for this specific indication in India remains pending.

NEW DELHI – Novo Nordisk’s blockbuster medication, Wegovy (semaglutide injection), continues to dominate international headlines following its recent regulatory milestones for treating metabolic-associated steatohepatitis (MASH), a severe form of fatty liver disease. However, as of July 2026, the drug’s formal marketing authorization in India remains strictly limited to weight management, correcting recent industry misconceptions regarding its approved indications in the country.

Clarifying Regulatory Approvals

Recent international regulatory bodies, including the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the U.S. Food and Drug Administration (FDA), have granted approval for semaglutide (Wegovy) to treat adults with MASH who present with moderate-to-advanced liver fibrosis. These approvals follow robust clinical trial data, such as the ESSENCE trial, which demonstrated that semaglutide can lead to the resolution of MASH and improvements in liver scarring.

In the Indian context, the Central Drugs Standard Control Organisation (CDSCO) has cleared Wegovy as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management. This approval extends to both adults with obesity and, as of mid-2026, adolescents aged 12 years and older with a body weight above 60 kg. Despite the global momentum behind the drug’s potential for liver health, Indian regulatory filings have not yet formally incorporated MASH or fatty liver disease as an approved therapeutic indication.

The Science Behind the Global Shift

The global medical community has shown growing interest in using GLP-1 receptor agonists—the class of drugs to which Wegovy belongs—to address liver disease. MASH occurs when excess fat buildup in the liver triggers inflammation and scarring, potentially progressing to cirrhosis or liver failure.

Clinical findings suggest that semaglutide improves insulin sensitivity and facilitates weight loss, both of which are critical factors in reducing liver fat. In international trials, a significant percentage of patients treated with semaglutide achieved MASH resolution without worsening their underlying liver fibrosis, offering a long-awaited medical intervention for a condition previously managed primarily through lifestyle modifications.

Impact on Indian Healthcare

For Indian patients and medical professionals, the distinction between global and local approvals is vital. While some practitioners may discuss Wegovy as an "off-label" consideration for patients with fatty liver disease who also meet obesity criteria, the drug is not currently marketed for liver-specific indications within India.

"Patients with fatty liver disease should rely on guidance from their healthcare providers, as Wegovy is a prescription-only medication and must be used under strict medical supervision," noted industry observers. The high cost of GLP-1 therapy and the necessity for long-term safety monitoring remain key considerations for its adoption in the Indian market.

Why It Matters

For citizens, distinguishing between official labels and global clinical developments is essential for patient safety. While Wegovy has shown potential for managing fatty liver disease internationally, any use in India must comply with local regulatory guidelines. Investors and stakeholders in the pharmaceutical sector are watching closely to see if Novo Nordisk will seek similar label expansions from the CDSCO in the future, as the prevalence of metabolic-related liver conditions continues to rise in urban Indian populations.

Key Facts at a Glance

• India Status: Wegovy is approved in India solely for chronic weight management (adults and adolescents aged 12+).

• Global Status: The drug has received regulatory approval for treating MASH (moderate-to-advanced fibrosis) in regions like the UK and the US.

• Mechanism: As a GLP-1 receptor agonist, it mimics hormones that regulate appetite and insulin sensitivity, indirectly benefiting liver fat levels.

• Clinical Data: International trials indicate that semaglutide can significantly reduce liver inflammation and scarring in selected patient populations.

Frequently Asked Questions

Is Wegovy approved to treat fatty liver disease in India? No. In India, Wegovy is currently approved only for weight management in adults and eligible adolescents. It is not formally approved for the treatment of fatty liver disease or MASH.

Can I take Wegovy for my liver condition? You should consult a qualified doctor before considering any medication. Wegovy is a prescription-only drug with specific eligibility criteria, and its use for conditions outside of its approved indication should be discussed with a medical professional.

Why are there reports of Wegovy being used for fatty liver disease? These reports stem from recent approvals in the US and UK, where regulators have authorized the drug for MASH based on clinical trial results. These international developments do not automatically apply to the Indian market.

What are the risks of using Wegovy? Common side effects include gastrointestinal issues such as nausea, vomiting, and diarrhea. It is not suitable for individuals with certain medical histories, such as a family history of specific thyroid cancers.

Source: CDSCO (Central Drugs Standard Control Organisation), MHRA (Medicines and Healthcare products Regulatory Agency), FDA Newsroom